About Medix Biochemica
Founded in 1986, Diaclone, now part of Medix Biochemica, develops immunology research reagents, monoclonal antibodies and immunoassay technologies for life science and diagnostic applications. The company specialises in tools for studying immune responses, biomarker expression and cellular signalling pathways. Its products enable researchers to detect and quantify cytokines, chemokines, growth factors and cell surface markers. Diaclone reagents are widely used in immunology, cancer research, immunotherapy, vaccinology, inflammation, allergy and autoimmune disease research. Based in Besançon, France, the company brings more than 30 years of expertise in antibody development and immunoassay design.
Diaclone’s portfolio includes monoclonal antibodies, recombinant proteins, recombinant antigens, ELISA kits, ELISpot assays and FluoroSpot reagents. These products support flow cytometry, cytokine profiling, biomarker discovery, immune monitoring, Western blotting and immunohistochemistry workflows. The company’s ELISA, ELISpot and FluoroSpot platforms help researchers analyse immune responses and protein biomarkers in human and animal samples. As part of Medix Biochemica, Diaclone continues to provide specialised immunology reagents and assay development expertise while maintaining its established product portfolio.
Europa Biosite’s subsidiaries distribute for Medix Biochemica in Denmark, Estonia, Finland, Germany, Iceland, Latvia, Lithuania, Norway and Sweden.